LEMS in Small Cell Lung Cancer: Definition, Pathophysiology, and Prognosis

Welcome back to another AJMC Fireside Chat series. In "LEMS in Small Cell Lung Cancer: Definition, Pathophysiology, and Prognosis," moderator Wade Iams, MD, MSCI is joined by Shiven Patel, MD, MBA, FACP to open the series on Lambert-Eaton myasthenic syndrome (LEMS) in small cell lung cancer.

Dr. Patel defines LEMS as a neuromuscular disorder in which the synapses between nerve and muscle stop firing properly. Weakness in the arms and legs is the most common presentation, though patients can also develop muscle pain, dry mouth, diplopia, and dysarthria from autonomic involvement. Dr. Patel calls the disease's link to small cell lung cancer (SCLC) fascinating, since the majority of LEMS cases occur in patients with SCLC. He explains the mechanism: the tumor expresses voltage-gated calcium channels (VGCCs), and the immune system, while attacking the cancer, mistakes these channels for a foreign antigen. The resulting autoantibodies target PQ-type VGCCs on presynaptic nerve terminals, blocking calcium entry and reducing acetylcholine release at the neuromuscular junction. That reduced acetylcholine release is what prevents the junction from firing normally and produces clinical weakness. Dr. Patel frames this immune response as directed against the cancer itself, and notes that patients with LEMS and SCLC tend to survive longer than SCLC patients without LEMS. Dr. Iams recaps the symptom picture, adding proximal muscle weakness, autonomic dysfunction, and diminished reflexes to the list, then asks why earlier recognition matters given this survival advantage. Dr. Patel responds that because these patients are likely to live longer, clinicians should not let them decline or die from LEMS symptoms while pursuing cancer treatment. With effective LEMS-specific treatment now available, early identification lets clinicians manage symptoms, protect quality of life, and preserve performance status so patients can tolerate full cancer-directed therapy rather than having treatment options narrowed by unaddressed neuromuscular decline.

Our next episode, "Evaluating Suspected LEMS: Differential Diagnosis and Palliative Care's Role," turns to how Dr. Patel evaluates a patient once LEMS is suspected, and why palliative care belongs in that conversation.